The feared phase of escalation began.
A Multicenter, phase I open-label dose escalation study of ABBV-085 an antibody drug conjugated in subjects with advanced solid tumors.
Choueiri, TK, Michaelson, MD, Posadas, EM, Sonpavde, GP, McDermott, DF, Nixon, AB, Liu, Y, Yuan, Z, Seon, BK, Walsh, M, Jivani, MA, Adams, BJ, and Theuer, CP. "An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma". The Oncologist 24, no. 2 (February 2019): 202-210.
11 The primary objective of this open-label Phase I dose-escalation study was to determine the MTD of oral buparlisib on a continuous daily schedule in adult Japanese patients with advanced solid tumors.
This was an open-label phase I dose-escalation study of volasertib in patients with advanced cancer conducted at two sites in Taiwan (NCT00969553).
This was an open-label, phase 1/2 dose-escalation, safety trial of intrathecal recombinant human heparan-N-sulfatase (rhHNS) administered via intrathecal drug delivery device (IDDD) for treating mucopolysaccharidosis IIIA (NCT01155778).
To test the hypothesis that vertical inhibition of the IGF pathway would be safe and tolerable, we designed an open label, phase I dose-escalation clinical trial of combined therapy with cixutumumab and selumetinib in patients with advanced solid tumours, including analysis of pharmacokinetic (PK) profiling and pharmacodynamic (PD) inhibition of downstream targets in an expansion cohort.
This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma.
This open-label Phase I dose-escalation study was conducted to determine the maximum tolerated dose of continuous daily buparlisib in Japanese patients with advanced solid tumors.
A phase I open-label dose-escalation study was conducted to define the safety, tolerability, and pharmacokinetics (PK) of PankoMab-GEX, a glyco-optimised humanised IgG1, with high affinity to a novel tumour-specific glycopeptide epitope of MUC1 (TA-MUC1) with excellent preclinical anti-tumour activity.
METHODS:We did an open-label, phase 1, dose-escalation study at seven clinics in the USA.
